Homologous recombination proficiency in ovarian and breast cancer patients
| Autor: | John Nemunaitis, Justin F. Creeden, Katelyn R. Einloth, Lance D. Dworkin, Laura Stanbery, Danae Hamouda, Cassidy Gillman, Nisha S. Nanavaty |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
DNA repair Genes BRCA2 Homologous recombination deficient BRCA Genes BRCA1 Breast Neoplasms Synthetic lethality Review Poly(ADP-ribose) Polymerase Inhibitors Bioinformatics Breast cancer Ovarian cancer Genetics medicine Humans Homologous recombination Gene Polymerase RC254-282 Ovarian Neoplasms biology business.industry Homologous recombination proficient Neoplasms. Tumors. Oncology. Including cancer and carcinogens Genetic Variation Recombinational DNA Repair medicine.disease PARP inhibitor Oncology Mutation biology.protein Female Poly(ADP-ribose) Polymerases business |
| Zdroj: | BMC Cancer BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021) |
| ISSN: | 1471-2407 |
| Popis: | Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, includingBRCA1andBRCA2results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) polymerase inhibitors (PARPi). However, response is limited in patients who are not HRD, highlighting the need for reliable and robust HRD testing. This manuscript will reviewBRCA1/2function and homologous recombination proficiency in respect to breast and ovarian cancer. The current standard testing methods for HRD will be discussed as well as trials leading to approval of PARPi’s. Finally, standard of care treatment and synthetic lethality will be reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|